Linked Life Data

19087985

Source:http://linkedlifedata.com/resource/pubmed/id/19087985

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2009-2-27
pubmed:abstractText
Drug resistance mechanisms can reduce response rate and duration in men with castration-resistant prostate cancer (CRPC) receiving docetaxel-based therapy. Patupilone (epothilone B), a microtubule-targeting agent, may be unaffected by some resistance mechanisms. Therefore, a phase II study assessed the patupilone safety and activity in CRPC patients with and without previous chemotherapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
1569-8041
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
492-7
pubmed:dateRevised
2009-8-10
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Phase II trial of weekly patupilone in patients with castration-resistant prostate cancer.
pubmed:affiliation
University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA. ahussain@som.umaryland.edu
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase II